Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80880
Name diffuse glioma, H3 G34 mutant
Definition A histone mutated tumor that has_material_basis_in mutations in codon 34 of the H3 histone family 3A protein.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer high grade glioma histone mutated tumor diffuse glioma, H3 G34 mutant

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04908176 Phase I Avapritinib + Midazolam A Drug-drug Interaction Study of Avapritinib and Midazolam Completed USA 0
NCT05429502 Phase Ib/II Ribociclib + Temozolomide + Topotecan Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU | AUS 1
NCT05457959 Phase I Nivolumab + Poly ICLC Ipilimumab + Nivolumab + Poly ICLC DC tumor cell lysate vaccine + Poly ICLC DC tumor cell lysate vaccine + Ipilimumab + Nivolumab + Poly ICLC DC tumor cell lysate vaccine + Nivolumab + Poly ICLC Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant Not yet recruiting USA 0
NCT06342908 Phase I Neoantigen-targeted ppDC Poly ICLC A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma Not yet recruiting 0